Cinqair (Reslizumab) 10mg/ml

Reslizumab, Cinqair
Description: Interleukin-5 Antagonist; Monoclonal Antibody, Anti-Asthmatic

“ALERT: US Boxed Warning

Anaphylaxis:
Anaphylaxis has been observed with reslizumab infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of reslizumab. Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after reslizumab administration by a health care professional prepared to manage anaphylaxis. Discontinue reslizumab immediately if the patient experiences signs or symptoms of anaphylaxis.”

CSA NA – FDA Approved – REMS (N) – Can Ship

Reslizumab, Cinqair is an interleukin-5 antagonist (IgG4 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils which are highly involved in the pathology of asthma.

Asthma

Before starting Reslizumab, Cinqair make sure your physician is aware of any allergies or medications you currently take, if you have an active or suspected helminth infection, are pregnant, or breastfeeding.  Reslizumab, Cinqair use has been associated with rare but serious adverse events such as anaphylaxis and malignancies.

IV: 3 mg/kg once every 4 weeks.

How to Take: For IV infusion only. Allow diluted solution to reach room temperature. Use an infusion set with an in-line, low protein-binding 0.2-micron filter such as polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate. Infuse over 20-to-50-minute period (may vary depending on total volume being infused) and then flush the IV administration set with NS after the infusion is finished. Observe patient during and for an appropriate time following infusion. Store intact vials in refrigerator at 2°C to 8°C (36°F to 46°F).  Store in original package to protect from light. After dilution in NS in infusion bag, administer immediately or store in a refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25°C (77°F), protected from light, for up to 16 hours

You Need to Avoid:  Do not administer as an IV push or bolus and do not infuse concomitantly in the same IV line with other agents. Do not freeze or shake prior to administration.  

Antibody development, increased creatine phosphokinase, myalgia, oropharyngeal pain, anaphylaxis 

1. What do I do if side effects are intolerable?
   If side effects are causing a lot of distress speak to your physician as soon as possible to discuss options.
2. What do I do if I have breakthrough symptoms?
   Your rescue inhaler which is usually salbutamol should still be carried and used for any breakthrough symptoms as prescribed.  This medication may eventually replace inhaled corticosteroid and is intended to reduce exacerbations but is not used as a rescue medication.